Unleash the power of RNAa technology to turn on nearly any beneficial genes

Ractigen Therapeutics's platform is based on a technology called RNAa (RNA activation) that utilizes small RNA duplexes to specifically target and up-regulate therapeutic genes. RNAa represents one of the few available technologies that could be translated into the clinic to treat disease by stimulating the production of endogenous genes. RNAa holds great promise for treating a wide variety of diseases including those undruggable by conventional therapies. The therapeutic benefits of RNAa have been demonstrated in a number of preclinical studies carried out in different disease models.


Ractigen Therapeutics is an early-stage biopharmaceutical company committed to bringing to market first-in-class products for the treatment of a wide variety of diseases, with a focus on cancer and debilitating genetic diseases. Founded in 2016, Ractigen is developing a rich pipeline of candidates with our most advanced product candidate entering IND-enabling development.

More infos
Long Cheng Li

Long-Cheng Li, M.D.

Co-Founder, President & CEO
Robert Place

Robert Place, Ph.D.

Co-Founder, CSO
Moorim Kang

Moo Rim Kang, Ph.D.

Vice President, Head of Early Drug Development

News & Events

Thursday, December 28, 2017  News

President of Ractigen wins government Innovation & Entrepreneurship award

[12/28/2017] As officially announced today by the Office of Leadership Body for Talents of Jiangsu Province, Dr. Long-Cheng Li, President of Ractigen Therapeutics, was among the winners for the Entrepreneurship prize from the 2017 Jiangsu Innovation and Entrepreneurship Program. This program,...